Close this search box.

Personalized Treatment Trials: Monitoring and Improving the Connection of Treatments to Patients

Study Aim

The study will deeply characterize patients before, during and after treatments are trialed through their General Practitioner (GP). Producing large scale data in combination with treatment outcome will be used to produce a predictive algorithm to improve the connection of patients to appropriate treatment options sooner.


  • Natalie Thomas, PhD
  • David Fineberg, MBBS, FRACGP, DCH
  • Neil McGregor, PhD
  • Michael Menden, PhD
  • Christopher Armstrong, PhD

Updates and Potential

  • IRB/Ethics commenced.
  • GP recruited as a PhD student.
  • Building out GP network across Victoria, needing 30 GPs to attract a large enough cohort for the study.
  • Ethics application approved for part 1 of the trial, part 2 and 3 ethics are being put together.
  • Part 1 is a pilot trial to assess clinical measures of value across a food test.
  • Developing collaborations with large biostatistics groups.

We’re conducting a study to closely watch how different treatments affect ME/CFS and Long COVID patients, using a very tailored approach. We’ll collect samples from patients before, during, and after their treatment to see what biological changes happen and how these relate to whether they feel better or not. This method will help us figure out which treatments work, why they work, and who they work best for.

We plan to study 200 patients over three years. Each patient will be part of the study for about 3 to 4 months, during which they will try 2 to 3 different treatments. This includes three visits to the clinic and involves analyzing many samples they provide, like blood and urine. This large collection of data from all the patients will help us make better predictions about which treatments are most likely to help others in the future.


The image depicts a healthcare setting where a young female healthcare worker, wearing a blue scrub top and a stethoscope around her neck, is holding the hands of an older patient.

  1. Pattern biology that corresponds to symptom/disease changes induced by treatment.
  2. Sample blood before and after exertion as a measure of improved exertion tolerance.
  3. Cluster patients based on biology-symptom dynamic and identify effective treatments.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669